Targeting connexin 43 with a-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1.

Targeting connexin 43 with a-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1. BMC Cancer. 2015 Apr 03; 15:296.

View in: PubMed

subject areas

Adaptor Proteins, Signal Transducing
Antineoplastic Agents
Breast Neoplasms
Cell Line, Tumor
Connexin 43
Drug Delivery Systems
Female
Humans
Quinazolines
Tamoxifen
Tumor Necrosis Factor Receptor-Associated Peptides and Proteins

authors with profiles

Joshua Matthew Rhett
Christina L Grek